<DOC>
	<DOCNO>NCT01234571</DOCNO>
	<brief_summary>Remodulin ( Treprostenil sodium ) synthetic prostacyclin analog available solution administration intravenous route . It approve treatment class I - pulmonary hypertension functional capacity stage III-IV . A key factor success pulmonary hypertension therapy maintain near constant blood level give medication along day . A sudden decrease blood level might lead rebound phenomenon ; abrupt increase pulmonary artery pressure might lead acute right ventricular failure even sudden death . As PHT patient suffer hemo-dialysis therapy due end-stage renal disease need document variation blood level along dialysis cycle .</brief_summary>
	<brief_title>Impact Hemo-dialysis Therapy Blood Levels Treprostenil End Stage Renal Disease Patients With Pulmonary Hypertension</brief_title>
	<detailed_description>After give informed consent 10 ml blood drawn study population follow occasion . - Baseline measurement immediately start HD therapy . - During hemo-dialysis therapy - every one hour . - After end hemo-dialysis therapy - every one hour ( total four measurement ) record recovery Treprostenil blood level .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>patient PAH receive chronic ( 3 month ) Treprostenil treatment administer intravenously single agent therapy maintain chronic hemodialysis therapy . Patients must stable condition least one month . Patients class I PAH include study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Pulmonary hypertension</keyword>
	<keyword>Remodulin ( Treprostenil sodium )</keyword>
	<keyword>End-stage renal disease</keyword>
	<keyword>Hemo-dialysis</keyword>
</DOC>